Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women's Health Initiative.

ABSTRACT:

Background

Oral menopausal hormone therapy causes venous thrombosis but whether biomarkers of thrombosis risk can identify women at risk is unknown.

Methods

We completed a nested case control study in the two Women's Health Initiative hormone trials; 27 347 women aged 50-79 were randomized to hormone therapy (conjugated equine estrogen with or without medroxyprogesterone acetate) or placebo. With 4 years follow-up, biomarkers were measured using stored baseline samples prior to starting treatment, and one-year later, in 215 women who developed thrombosis and 867 controls.

Results

Overall, lower protein C and free protein S, and higher D-dimer, prothrombin fragment 1.2 and plasmin-antiplasmin complex were associated with risk of future thrombosis with odds ratios rangi

SUBMITTER: Cushman M 

PROVIDER: S-EPMC5974918 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature